Atherogenic Effect of Interleukin-2 and Antiatherogenic Effect of Interleukin-2 Antibody in Apo-E-Deficient Mice

Abstract

Growing evidence suggests that atherosclerosis is an immune-mediated inflammatory process and that cytokines participate as mediators in this process. Of the cytokines, interleukins, which are released from both immune and nonimmune cells of vascular wall, are found to have multiple effects. Interleukin-2 (IL-2), a cytokine produced by activated T-lymphocytes, has been found to further activate the T cells and may potentially enhance atherogenesis. Apo-E-deficient mice fed with atherogenic diet were injected intraperitoneally twice a week with placebo, IL-2, or anti-IL-2 antibody for a period of 6 weeks. Group 1 (n=6) was injected with bovine serum albumin (BSA) in phosphate-buffered saline (PBS) and served as controls. Group 2 (n=6) was injected with 2x10⁴ units of recombinant murine IL-2 (rmIL-2) per dose reconstituted with BSA in PBS. Group 3 (n=6) was injected with 5 µg of anti-IL-2 per dose reconstituted with BSA in PBS. Aortic sections were analyzed and atherosclerotic burden was quantified. Compared to controls, injection of IL-2 increased measures of atherosclerosis such as the average lesion score (10.7 ±0.5 vs 9.3 ±1.1, p=0.04) and the lesion size as a fraction of aortic area (0.51 ±0.03 vs 0.41 ±0.05, p=0.01). Injection of anti-IL-2 had a profound antiatherogenic effect. It significantly reduced the average number of lesions per cross section (2.6 ±0.6 vs 4.3 ±0.6, p=0.03), the average lesion score (4.6 ±1.9 vs 9.3 ±1.1, p=0.02), the lesion area/circumference (0.35 ±0.08 vs 0.62 ±0.10, p=0.007), and the lesion size/aortic area (0.23 ±0.07 vs 0.41 ±0.05, p=0.03). These results indicate that IL-2 is an atherogenic cytokine in apo-E-deficient mice and anti-IL-2 is protective against atherosclerosis. This may have important clinical implications in modifying the atherosclerotic process.

Get full access to this article

View all access options for this article.

References

Frostegard J : Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev 1:233-237, 2002.

Hansson GK : Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J 69(suppl 1):S38-S41, 1993.

Rus HG , Vlaicu R , Niculescu F : Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127:263-271, 1996.

DePalma RG , Hayes VW , Cafferata HT , et al : Cytokine signatures in atherosclerotic claudicants. J Surg Res 111:215-221, 2003.

Katz MF , Farber HW , Dodds-Stitt Z , et al : Serotonin-stimulated aortic endothelial cells secrete a novel T-lymphocyte chemotactic and growth factor. J Leukoc Biol 55:567-573, 1994.

Watanabe T , Haraoka S , Shimokama T : Inflammatory and immunological nature of atherosclerosis. Int J Cardiol 54(suppl):S51-S60, 1996.

Nakashima Y , Plump AS , Raines EW , et al : Apo-E-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14:133-140, 1994.

Tamminen M , Mottino G , Qiao JH , et al : Ultrastructure of early lipid accumulation in apo-E-deficient mice. Arterioscler Thromb Vasc Biol 19:847-853, 1999.

Ettinghausen SE , Lipford EH III , Mule JJ , et al : Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol 135:1488-1497, 1985.

10.

Courtney LP , Phelps JL , Karavodin LM : An anti-IL-2 antibody increases serum half-life and improves anti-tumour efficacy of human recombinant interleukin-2. Immunopharmacology 28:223-232, 1994.

11.

Reddick RL , Zhang SH , Maeda N : Atherosclerosis in mice lacking apo-E. Evaluation of lesional development and progression. Arterioscler Thromb 14:141-147, 1994.

12.

Paigen B , Havens MB , Morrow A : Effect of 3-methyl-cholanthrene on the development of aortic lesions in mice. Cancer Res 45:3850-3855, 1985.

13.

Cheever MA , Thompson JA , Kern DE , et al : Interleukin-2 administered in vivo: Influence of IL-2 route and timing on T-cell growth. J Immunol 134:3895-3900, 1985.

14.

Kelly ME , Clay MA , Mistry MJ , et al : Apolipoprotein-E inhibition of proliferation of mitogen activated lymphocytes: Production of interleukin-2 with reduced biological activity. Cell Immunol 159:124-139, 1994.

15.

Mistry MJ , Clay MA , Kelly ME , et al : Apolipoprotein-E restricts interleukin-dependent T-lymphocyte proliferation at the G1A/G1B boundary. Cell Immunol 160:14-23, 1995.

16.

Kirii H , Niwa T , Yamada Y , et al : Lack of Interleukin-1 (beta) decreases the severity of atherosclerosis in APO-E-deficient mice. Arterioscler Thromb Vasc Biol 23:656-660, 2003.

17.

Huber SA , Sakkinen P , Conze D , et al : Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19:2364-2367, 1999.

18.

Caligiuri G , Rudling M , Ollivier V , et al : Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apo-E knockout mice. Mol Med 9:10-17, 2003.

19.

Lee TS , Yen HC , Pan CC , et al : The role of IL-12 in the development of atherosclerosis in Apo-E-deficient mice. Arterioscler Thromb Vasc Biol 19:734-742, 1999.

20.

Elhage R , Jawien J , Rudling M , et al : Reduced atherosclerosis in IL-18-deficient Apo-E knockout mice. Cardiovasc Res 59:234-240, 2003.

21.

Whitman SC , Ravisankar P , Daugherty A : IL-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 90:E34-E39, 2002.